Posts Tagged ‘Biotech’
CHUV, Alithea Genomics and PanGene partner to develop a pan-cancer blood test
The three partners secured a €1 million ($1.1 million) in Eurostars grant funding to develop a first of a king pan-cancer blood test to guide immune checkpoint inhibitor (ICI) therapy. The consortium combines an expertise in clinical research, transcriptomics and kinomic profiling to take a radically new approach to identify a multi-omics biomarker profile…
Read MoreBioAlps and the Swiss Health Valley
Listen to Magali Bischof, BioAlps Secretary General, on Beyond Biotech podcast speaking about the Swiss Health Valley and the role of BioAlps association. Here is the transcription of the interview. ▶️ Listen to the podcast on Labiotech.eu | From 00:31:50 to 47:30 Could you tell us about BioAlps – when it was formed,…
Read MoreModerna plans to produce a RNA vaccine against RSV in Valais
Moderna, which developed one of the first messenger RNA vaccines against Covid-19, has disclosed positive preliminary results for a trial against the Respiratory Syncytial Virus (RSV), which causes bronchiolitis, in the elderly. The vaccine will be produced in Boston (USA) and in Visp (Switzerland) The phase 3 trial is being conducted in a double-blind…
Read MoreNeurosoft Bioelectronics receives ISO Certification for its Quality Management System
Neurosoft Bioelectronics SA, a startup developing implantable brain-computer interfaces, announces that it has received ISO 13485:2016 Certification by TÜV SÜD for its Quality Management System. This is a major milestone for Neurosoft Bioelectronics as it brings the company one step closer to its first clinical studies and regulatory approval of their first product :…
Read MoreA CHF 1 billion contract for Bachem Group
The contract covers the delivery of a large volume of peptides over a five-year period from 2025-2029, and follows the conclusion of two large volume contracts announced in September 2022. The customer’s name is undisclosed. Bachem is pursuing an investment program across all sites to expand capacity, especially in Vionnaz (Switzerland). A modern large-scale…
Read MoreBridge – Proof of Concept
A 12-month programme to develop your idea into a prototype. Apply before 1 June 2026. BRIDGE is a funding programme run by the Swiss National Science Fondation (SNSF) and Innosuisse, that has been funding projects between basic research and innovation since 2017. Support is provided to researchers whose results have potential for an innovative product…
Read MoreSwissfillon becomes ten23 health
ten23 health®, a global contract development and manufacturing organization (CDMO) announces the change in branding of its in Visp, Switzerland based filling operation from swissfillon to ten23 health. This represents a natural progression since the acquisition of swissfillon by ten23 health in October 2021 and is intended to unify the company’s operations under a…
Read MoreSTALICLA signs exclusive in-licensing agreement with Novartis for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications. STALICLA SA, a clinical-stage, Geneva-based, biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, announces that it has entered into an exclusive…
Read MoremimiX biotherapeutics launches a funding round to accelerate clinical translation of FastSkin®
mimiX biotherapeutics launches a funding round to accelerate clinical translation of FastSkin® MIMIX BIOTHERAPEUTICS LTD, a Swiss medical technology company focused on life sciences, with a next-generation 3D bioprinting platform using proprietary Sound Induced Morphogenesis (SIM), announces that the company is accelerating the clinical translation of FastSkin®. FastSkin® is an advanced dermal substitute for acute…
Read MoreSwiss research: the pharmaceutical industry is the leading investor in 2021
In 2021, private companies spent CHF 16.8 billion in Switzerland on in-house research and development (R&D) activities. This represents an increase of +4% per year since 2019, the year of the last survey, according to a survey carried out by the Federal Statistical Office (FSO) in partnership with economiesuisse. With an amount of CHF 6.2…
Read More